CTOs on the Move

Glendale Adventist Medical Center

www.glendaleadventist.com

 
The purpose of the Healthcare Foundation is to support the work and mission of Glendale Adventist Medical Center through philanthropy. Foundation responsibilities include the receipt and disbursement of all gifts to the Medical Center, as well as the
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

The Tech Group Subsidiary of West Pharmaceutical Services

The Tech Group, Inc Subsidiary of West Pharmaceutical Services, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The Tech Group, Inc Subsidiary of West Pharmaceutical Services, Inc. is based in Scottsdale, AZ. You can find more information on The Tech Group, Inc Subsidiary of West Pharmaceutical Services, Inc. at www.techgroup.com

Heartland Regional Medical Center

Heartland Regional Medical Center is offering patients and physicians in southern Illinois access to the latest diagnositc imaging technology. Our 64 Slice CT (computed tomography) scanner produces crisp, detailed images of the body in just seconds. Our

Crouse

Crouse Hospital has been caring for generations of Central New Yorkers since 1887. Our mission is to provide the best in patient care by exceeding the expectations of our patients and to promote community health. A private, not-for-profit hospital, Crouse is licensed for 506 acute-care beds and 57 bassinets. We serve more than 23,000 inpatients, 66,000 emergency services patients and more than 250,000 outpatients a year from a 15-county area in Central and Northern New York.  

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.